Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition.
The association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed among 126,920 post-menopausal women recruited into the European Prospective Investigation into Cancer and Nutrition. After an average of 9-year follow-up, 424 incident ovarian cancers were diagnosed. Cox...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826270887712653312 |
|---|---|
| author | Tsilidis, K Allen, N Key, T Dossus, L Kaaks, R Bakken, K Lund, E Fournier, A Dahm, C Overvad, K Hansen, L Tjønneland, A Rinaldi, S Romieu, I Boutron-Ruault, M Clavel-Chapelon, F Lukanova, A Boeing, H Schütze, M Benetou, V Palli, D Berrino, F Galasso, R Tumino, R Sacerdote, C |
| author_facet | Tsilidis, K Allen, N Key, T Dossus, L Kaaks, R Bakken, K Lund, E Fournier, A Dahm, C Overvad, K Hansen, L Tjønneland, A Rinaldi, S Romieu, I Boutron-Ruault, M Clavel-Chapelon, F Lukanova, A Boeing, H Schütze, M Benetou, V Palli, D Berrino, F Galasso, R Tumino, R Sacerdote, C |
| author_sort | Tsilidis, K |
| collection | OXFORD |
| description | The association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed among 126,920 post-menopausal women recruited into the European Prospective Investigation into Cancer and Nutrition. After an average of 9-year follow-up, 424 incident ovarian cancers were diagnosed. Cox models adjusted for body mass index, smoking status, unilateral ovariectomy, simple hysterectomy, age at menarche, number of full-term pregnancies, and duration of oral contraceptives were used. Compared with baseline never use, current use of any HT was positively associated with risk (HR [hazard ratio], 1.29; 95% CI [confidence interval], 1.01-1.65), while former use was not (HR, 0.96; 95% CI, 0.70-1.30). Current estrogen-only HT was associated with a 63% higher risk (HR, 1.63; 95% CI, 1.08-2.47), while current estrogen plus progestin was associated with a smaller and non-significant higher risk (HR, 1.20; 95% CI, 0.89-1.62). Use of tibolone was associated with a twofold greater risk (HR, 2.19; 95% CI, 1.06-4.50), but was based on small numbers. In conclusion, women who currently use HT have a moderate increased risk of ovarian cancer, and which may be stronger for estrogen-only than estrogen plus progestin preparations. |
| first_indexed | 2024-03-06T21:47:55Z |
| format | Journal article |
| id | oxford-uuid:4a3ee548-19e8-4980-8508-fe1f8906698d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:47:55Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:4a3ee548-19e8-4980-8508-fe1f8906698d2022-03-26T15:36:24ZMenopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4a3ee548-19e8-4980-8508-fe1f8906698dEnglishSymplectic Elements at Oxford2011Tsilidis, KAllen, NKey, TDossus, LKaaks, RBakken, KLund, EFournier, ADahm, COvervad, KHansen, LTjønneland, ARinaldi, SRomieu, IBoutron-Ruault, MClavel-Chapelon, FLukanova, ABoeing, HSchütze, MBenetou, VPalli, DBerrino, FGalasso, RTumino, RSacerdote, CThe association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed among 126,920 post-menopausal women recruited into the European Prospective Investigation into Cancer and Nutrition. After an average of 9-year follow-up, 424 incident ovarian cancers were diagnosed. Cox models adjusted for body mass index, smoking status, unilateral ovariectomy, simple hysterectomy, age at menarche, number of full-term pregnancies, and duration of oral contraceptives were used. Compared with baseline never use, current use of any HT was positively associated with risk (HR [hazard ratio], 1.29; 95% CI [confidence interval], 1.01-1.65), while former use was not (HR, 0.96; 95% CI, 0.70-1.30). Current estrogen-only HT was associated with a 63% higher risk (HR, 1.63; 95% CI, 1.08-2.47), while current estrogen plus progestin was associated with a smaller and non-significant higher risk (HR, 1.20; 95% CI, 0.89-1.62). Use of tibolone was associated with a twofold greater risk (HR, 2.19; 95% CI, 1.06-4.50), but was based on small numbers. In conclusion, women who currently use HT have a moderate increased risk of ovarian cancer, and which may be stronger for estrogen-only than estrogen plus progestin preparations. |
| spellingShingle | Tsilidis, K Allen, N Key, T Dossus, L Kaaks, R Bakken, K Lund, E Fournier, A Dahm, C Overvad, K Hansen, L Tjønneland, A Rinaldi, S Romieu, I Boutron-Ruault, M Clavel-Chapelon, F Lukanova, A Boeing, H Schütze, M Benetou, V Palli, D Berrino, F Galasso, R Tumino, R Sacerdote, C Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. |
| title | Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. |
| title_full | Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. |
| title_fullStr | Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. |
| title_full_unstemmed | Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. |
| title_short | Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. |
| title_sort | menopausal hormone therapy and risk of ovarian cancer in the european prospective investigation into cancer and nutrition |
| work_keys_str_mv | AT tsilidisk menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT allenn menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT keyt menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT dossusl menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT kaaksr menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT bakkenk menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT lunde menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT fourniera menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT dahmc menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT overvadk menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT hansenl menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT tjønnelanda menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT rinaldis menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT romieui menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT boutronruaultm menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT clavelchapelonf menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT lukanovaa menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT boeingh menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT schutzem menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT benetouv menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT pallid menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT berrinof menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT galassor menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT tuminor menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition AT sacerdotec menopausalhormonetherapyandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition |